Novel transcript antisense to coagulation factor II thrombin receptor

This entry refers to a **natural antisense transcript (NAT)** overlapping the F2R gene locus. Such transcripts are a class of long non-coding RNAs expressed from the strand opposite a protein-coding gene. NATs can regulate their sense gene through multiple mechanisms—including transcriptional interference, masking of regulatory elements, formation of double-stranded RNA for RNA interference or editing, and recruitment of chromatin-modifying enzymes for epigenetic regulation[2][3][4]. The antisense transcript to F2R is not a protein and has no established role as a therapeutic target, drug-interacting receptor, or biomarker. Current evidence suggests that antisense RNAs such as this are primarily involved in *endogenous gene regulation*, influencing transcription, mRNA stability, chromatin state, and possibly noise dampening in gene expression[2][3][4]. No direct disease-association or drug interaction is documented for this transcript. Summary: This "target" is not a conventional drug target or receptor, but rather a non-coding RNA transcript with gene regulatory potential. There is no evidence supporting its use as a therapeutic target, nor any described drugs, biomarkers, or safety issues directly related to it.

Other names

Novel transcript, antisense to F2RENSG00000225407

No direct drug mechanism of action; regulation is through antisense-mediated gene regulation or chromatin effects[2][3][4]